Elbion Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 47

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $18M

Elbion General Information

Description

Provider of pharmaceutical research and development services. The company operates as a specialty pharmaceutical company focused on the development and commercialization of therapeutics for neurological diseases and immunological disorders.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Meissner Straße 191
  • 01445 Radebeul
  • Germany
+49 0351
Primary Industry
Drug Delivery
Other Industries
Pharmaceuticals
Acquirer
Corporate Office
  • Meissner Straße 191
  • 01445 Radebeul
  • Germany
+49 0351

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Elbion Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 14-Nov-2008 $18M Completed Generating Revenue
1. Early Stage VC (Series A) 10-Jul-2005 Completed Generating Revenue
To view Elbion’s complete valuation and funding history, request access »

Elbion Patents

Elbion Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20090143367-A1 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) Active 30-Nov-2007
US-7875618-B2 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) Inactive 30-Nov-2007
AU-2008329072-A1 Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 Inactive 30-Nov-2007
CA-2706986-A1 Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 Inactive 30-Nov-2007
EP-2227472-A1 Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 Inactive 30-Nov-2007 C07D487/04
To view Elbion’s complete patent history, request access »

Elbion Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Elbion Former Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
3i Group PE/Buyout Minority
BayTech Venture Capital Venture Capital Minority
Burrill & Co Merchant Banking Firm Minority
Deutsche Venture Capital Corporate Venture Capital Minority
Idinvest Partners PE/Buyout Minority
You’re viewing 5 of 10 investors. Get the full list »

Elbion Investments & Acquisitions (2)

Elbion’s most recent deal was a Corporate Asset Purchase with DrugAbuse Sciences (Late-Stage Drug Candidate and Product Rights). The deal was made on 19-Jan-2007.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
DrugAbuse Sciences (Late-Stage Drug Candidate and Product Rights) 19-Jan-2007 Corporate Asset Purchase Buildings and Property
4 AZA Bioscience 12-Aug-2006 Merger/Acquisition Drug Discovery
To view Elbion’s complete investments and acquisitions history, request access »

Elbion FAQs

  • When was Elbion founded?

    Elbion was founded in 2002.

  • Where is Elbion headquartered?

    Elbion is headquartered in Radebeul, Germany.

  • What is the size of Elbion?

    Elbion has 47 total employees.

  • What industry is Elbion in?

    Elbion’s primary industry is Drug Delivery.

  • Is Elbion a private or public company?

    Elbion is a Private company.

  • What is the current valuation of Elbion?

    The current valuation of Elbion is .

  • What is Elbion’s current revenue?

    The current revenue for Elbion is .

  • How much funding has Elbion raised over time?

    Elbion has raised $42.2M.

  • Who are Elbion’s investors?

    3i Group, BayTech Venture Capital, Burrill & Co, Deutsche Venture Capital, and Idinvest Partners are 5 of 10 investors who have invested in Elbion.

  • When was Elbion acquired?

    Elbion was acquired on 14-Nov-2008.

  • Who acquired Elbion?

    Elbion was acquired by Biotie Therapies.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process